|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||39.46|
|Dividend & Yield||0.78 (3.11%)|
|1y Target Est||N/A|
Japan's Nikkei share average fell to a more than one-week low on Tuesday morning after cyclical stocks lost ground as a stronger yen hit sentiment, while Toshiba Corp rallied after news a U.S. hedge fund ...
A U.S. appeals court ruled on Monday that a patent on Takeda Pharmaceutical Co Ltd's cancer treatment Velcade is valid, pushing back the date when generic drug makers including Teva Pharmaceutical Industries Ltd and Mylan NV will be allowed to launch lower-cost versions of the drug in the United States. The U.S. Court of Appeals for the Federal Circuit rejected arguments by a dozen generic drug companies that the Velcade patent was obvious and should not have been granted. The ruling, which reversed a lower court, will allow Takeda to sell Velcade exclusively until the patent expires in 2022.
Rating Action: Moody's assigns A1 rating to Takeda Pharmaceutical's USD notes. Global Credit Research- 13 Jul 2017. USD500 million of new debt rated.